Literature DB >> 10651933

Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp.

K Kailasapathy1, J Chin.   

Abstract

The present paper provides an overview on the use of probiotic organisms as live supplements, with particular emphasis on Lactobacillus acidophilus and Bifidobacterium spp. The therapeutic potential of these bacteria in fermented dairy products is dependent on their survival during manufacture and storage. Probiotic bacteria are increasingly used in food and pharmaceutical applications to balance disturbed intestinal microflora and related dysfunction of the human gastrointestinal tract. Lactobacillus acidophilus and Bifidobacterium spp. have been reported to be beneficial probiotic organisms that provide excellent therapeutic benefits. The biological activity of probiotic bacteria is due in part to their ability to attach to enterocytes. This inhibits the binding of enteric pathogens by a process of competitive exclusion. Attachment of probiotic bacteria to cell surface receptors of enterocytes also initiates signalling events that result in the synthesis of cytokines. Probiotic bacteria also exert an influence on commensal micro-organisms by the production of lactic acid and bacteriocins. These substances inhibit growth of pathogens and also alter the ecological balance of enteric commensals. Production of butyric acid by some probiotic bacteria affects the turnover of enterocytes and neutralizes the activity of dietary carcinogens, such as nitrosamines, that are generated by the metabolic activity of commensal bacteria in subjects consuming a high-protein diet. Therefore, inclusion of probiotic bacteria in fermented dairy products enhances their value as better therapeutic functional foods. However, insufficient viability and survival of these bacteria remain a problem in commercial food products. By selecting better functional probiotic strains and adopting improved methods to enhance survival, including the use of appropriate prebiotics and the optimal combination of probiotics and prebiotics (synbiotics), an increased delivery of viable bacteria in fermented products to the consumers can be achieved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651933     DOI: 10.1046/j.1440-1711.2000.00886.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  96 in total

1.  Influence of whole peptidoglycan of bifidobacterium on cytotoxic effectors produced by mouse peritoneal macrophages.

Authors:  L S Wang; H M Zhu; D Y Zhou; Y L Wang; W D Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Development of a flow cytometric method to analyze subpopulations of bacteria in probiotic products and dairy starters.

Authors:  Christine J Bunthof; Tjakko Abee
Journal:  Appl Environ Microbiol       Date:  2002-06       Impact factor: 4.792

3.  Bacteriological evaluation of dog and cat diets that claim to contain probiotics.

Authors:  J Scott Weese; Luis Arroyo
Journal:  Can Vet J       Date:  2003-03       Impact factor: 1.008

4.  In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice.

Authors:  Elizabeth A Griffiths; Linda C Duffy; Floyd L Schanbacher; Haiping Qiao; Diane Dryja; Allen Leavens; Jon Rossman; Gary Rich; Douglas Dirienzo; Pearay L Ogra
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

5.  Survival of bifidobacteria in adult intestinal tract.

Authors:  M Grmanová; E Vlková; V Rada; I Homutová
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

6.  Supercritical CO2 interpolymer complex encapsulation improves heat stability of probiotic bifidobacteria.

Authors:  M S Thantsha; P W Labuschagne; C I Mamvura
Journal:  World J Microbiol Biotechnol       Date:  2013-08-30       Impact factor: 3.312

7.  Viability of human-derived probiotic lactobacilli in ice cream produced with sucrose and aspartame.

Authors:  Gülden Başyiğit; Hakan Kuleaşan; Aynur G Karahan
Journal:  J Ind Microbiol Biotechnol       Date:  2006-04-26       Impact factor: 3.346

8.  Differential activities of four Lactobacillus casei promoters during bacterial transit through the gastrointestinal tracts of human-microbiota-associated mice.

Authors:  R Oozeer; J P Furet; N Goupil-Feuillerat; J Anba; J Mengaud; G Corthier
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

9.  Initiation of protein synthesis by a labeled derivative of the Lactobacillus casei DN-114 001 strain during transit from the stomach to the cecum in mice harboring human microbiota.

Authors:  R Oozeer; D D G Mater; N Goupil-Feuillerat; G Corthier
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

Review 10.  A review on anti-adhesion therapies of bacterial diseases.

Authors:  Arezoo Asadi; Shabnam Razavi; Malihe Talebi; Mehrdad Gholami
Journal:  Infection       Date:  2018-10-01       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.